nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Niacin—atherosclerosis	0.223	0.3	CbGbCtD
Methylnaltrexone—CYP2D6—Simvastatin—atherosclerosis	0.177	0.237	CbGbCtD
Methylnaltrexone—CYP2D6—Lovastatin—atherosclerosis	0.173	0.232	CbGbCtD
Methylnaltrexone—CYP2D6—Pravastatin—atherosclerosis	0.173	0.232	CbGbCtD
Methylnaltrexone—Redness—Niacin—atherosclerosis	0.0103	0.0649	CcSEcCtD
Methylnaltrexone—Naloxone—TLR4—atherosclerosis	0.00771	0.712	CrCbGaD
Methylnaltrexone—Flatulence—Rosuvastatin—atherosclerosis	0.0041	0.0259	CcSEcCtD
Methylnaltrexone—Flatulence—Lovastatin—atherosclerosis	0.00348	0.022	CcSEcCtD
Methylnaltrexone—Erythema—Ezetimibe—atherosclerosis	0.00346	0.0219	CcSEcCtD
Methylnaltrexone—Flatulence—Ezetimibe—atherosclerosis	0.00341	0.0216	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00333	0.0211	CcSEcCtD
Methylnaltrexone—Erythema—Simvastatin—atherosclerosis	0.0033	0.0209	CcSEcCtD
Methylnaltrexone—Flatulence—Simvastatin—atherosclerosis	0.00325	0.0206	CcSEcCtD
Methylnaltrexone—Erythema—Niacin—atherosclerosis	0.00303	0.0192	CcSEcCtD
Methylnaltrexone—Flatulence—Niacin—atherosclerosis	0.00299	0.0189	CcSEcCtD
Methylnaltrexone—Flatulence—Pravastatin—atherosclerosis	0.00294	0.0186	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00293	0.0185	CcSEcCtD
Methylnaltrexone—Pain—Rosuvastatin—atherosclerosis	0.00291	0.0184	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00278	0.0176	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ezetimibe—atherosclerosis	0.00277	0.0175	CcSEcCtD
Methylnaltrexone—Skin disorder—Ezetimibe—atherosclerosis	0.00274	0.0173	CcSEcCtD
Methylnaltrexone—Oedema—Simvastatin—atherosclerosis	0.00269	0.017	CcSEcCtD
Methylnaltrexone—Abdominal pain—Rosuvastatin—atherosclerosis	0.00269	0.017	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00256	0.0162	CcSEcCtD
Methylnaltrexone—Oedema—Niacin—atherosclerosis	0.00247	0.0156	CcSEcCtD
Methylnaltrexone—Pain—Lovastatin—atherosclerosis	0.00246	0.0156	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00244	0.0154	CcSEcCtD
Methylnaltrexone—Oedema—Pravastatin—atherosclerosis	0.00244	0.0154	CcSEcCtD
Methylnaltrexone—Pain—Ezetimibe—atherosclerosis	0.00242	0.0153	CcSEcCtD
Methylnaltrexone—Skin disorder—Niacin—atherosclerosis	0.0024	0.0152	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Niacin—atherosclerosis	0.00239	0.0151	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00236	0.0149	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Pravastatin—atherosclerosis	0.00236	0.0149	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00233	0.0147	CcSEcCtD
Methylnaltrexone—Diarrhoea—Rosuvastatin—atherosclerosis	0.00233	0.0147	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00231	0.0146	CcSEcCtD
Methylnaltrexone—Pain—Simvastatin—atherosclerosis	0.0023	0.0146	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lovastatin—atherosclerosis	0.00228	0.0144	CcSEcCtD
Methylnaltrexone—Dizziness—Rosuvastatin—atherosclerosis	0.00225	0.0142	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ezetimibe—atherosclerosis	0.00223	0.0141	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0022	0.0139	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—atherosclerosis	0.00216	0.2	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Niacin—atherosclerosis	0.00214	0.0135	CcSEcCtD
Methylnaltrexone—Abdominal pain—Simvastatin—atherosclerosis	0.00213	0.0135	CcSEcCtD
Methylnaltrexone—Pain—Niacin—atherosclerosis	0.00212	0.0134	CcSEcCtD
Methylnaltrexone—Pain—Pravastatin—atherosclerosis	0.00208	0.0132	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Niacin—atherosclerosis	0.00202	0.0128	CcSEcCtD
Methylnaltrexone—Nausea—Rosuvastatin—atherosclerosis	0.00202	0.0128	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00199	0.0126	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lovastatin—atherosclerosis	0.00197	0.0125	CcSEcCtD
Methylnaltrexone—Abdominal pain—Niacin—atherosclerosis	0.00196	0.0124	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ezetimibe—atherosclerosis	0.00193	0.0122	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pravastatin—atherosclerosis	0.00193	0.0122	CcSEcCtD
Methylnaltrexone—Dizziness—Lovastatin—atherosclerosis	0.00191	0.012	CcSEcCtD
Methylnaltrexone—Dizziness—Ezetimibe—atherosclerosis	0.00187	0.0118	CcSEcCtD
Methylnaltrexone—Diarrhoea—Simvastatin—atherosclerosis	0.00184	0.0116	CcSEcCtD
Methylnaltrexone—Vomiting—Lovastatin—atherosclerosis	0.00183	0.0116	CcSEcCtD
Methylnaltrexone—Vomiting—Ezetimibe—atherosclerosis	0.0018	0.0114	CcSEcCtD
Methylnaltrexone—Dizziness—Simvastatin—atherosclerosis	0.00178	0.0113	CcSEcCtD
Methylnaltrexone—Vomiting—Simvastatin—atherosclerosis	0.00171	0.0108	CcSEcCtD
Methylnaltrexone—Nausea—Lovastatin—atherosclerosis	0.00171	0.0108	CcSEcCtD
Methylnaltrexone—Diarrhoea—Niacin—atherosclerosis	0.00169	0.0107	CcSEcCtD
Methylnaltrexone—Nausea—Ezetimibe—atherosclerosis	0.00168	0.0106	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pravastatin—atherosclerosis	0.00167	0.0105	CcSEcCtD
Methylnaltrexone—Dizziness—Niacin—atherosclerosis	0.00164	0.0103	CcSEcCtD
Methylnaltrexone—Dizziness—Pravastatin—atherosclerosis	0.00161	0.0102	CcSEcCtD
Methylnaltrexone—Nausea—Simvastatin—atherosclerosis	0.0016	0.0101	CcSEcCtD
Methylnaltrexone—Vomiting—Niacin—atherosclerosis	0.00157	0.00994	CcSEcCtD
Methylnaltrexone—Vomiting—Pravastatin—atherosclerosis	0.00155	0.00979	CcSEcCtD
Methylnaltrexone—Nausea—Niacin—atherosclerosis	0.00147	0.00929	CcSEcCtD
Methylnaltrexone—Nausea—Pravastatin—atherosclerosis	0.00145	0.00914	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—atherosclerosis	0.000962	0.0889	CrCbGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CASR—atherosclerosis	0.000165	0.00193	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CNR2—atherosclerosis	0.000164	0.00193	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—atherosclerosis	0.000164	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000161	0.00189	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.000161	0.00188	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL8—atherosclerosis	0.00016	0.00188	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—UTS2—atherosclerosis	0.000156	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR2—atherosclerosis	0.000153	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000153	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—EDN1—atherosclerosis	0.000152	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—AKT1—atherosclerosis	0.000151	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL5—atherosclerosis	0.000151	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CX3CR1—atherosclerosis	0.00015	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CASR—atherosclerosis	0.00015	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—AGT—atherosclerosis	0.000149	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000147	0.00172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRH1—atherosclerosis	0.000143	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL3—atherosclerosis	0.000141	0.00166	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000141	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR2—atherosclerosis	0.000141	0.00165	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTM1—atherosclerosis	0.000141	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR2—atherosclerosis	0.000139	0.00163	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTM1—atherosclerosis	0.000139	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—F2—atherosclerosis	0.000138	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GHRL—atherosclerosis	0.000137	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000136	0.0016	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL8—atherosclerosis	0.000136	0.00159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA4—atherosclerosis	0.000133	0.00156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EDNRA—atherosclerosis	0.000128	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR2—atherosclerosis	0.000128	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000128	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—AGT—atherosclerosis	0.000126	0.00148	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GHRL—atherosclerosis	0.000125	0.00146	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL2—atherosclerosis	0.000123	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL4—atherosclerosis	0.000122	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—KNG1—atherosclerosis	0.00012	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AGTR1—atherosclerosis	0.00012	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL3—atherosclerosis	0.00012	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR2—atherosclerosis	0.000119	0.00139	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000119	0.00139	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—F2—atherosclerosis	0.000116	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GHRL—atherosclerosis	0.000116	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA2—atherosclerosis	0.000114	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA4—atherosclerosis	0.000112	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KNG1—atherosclerosis	0.000109	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—UTS2—atherosclerosis	0.000109	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AGTR1—atherosclerosis	0.000109	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR2—atherosclerosis	0.000108	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDNRA—atherosclerosis	0.000108	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000108	0.00126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GHRL—atherosclerosis	0.000105	0.00123	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CX3CR1—atherosclerosis	0.000105	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASR—atherosclerosis	0.000105	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL2—atherosclerosis	0.000104	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL4—atherosclerosis	0.000103	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CX3CL1—atherosclerosis	0.000103	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—KNG1—atherosclerosis	0.000102	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—EDN1—atherosclerosis	0.000102	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AGTR1—atherosclerosis	0.000101	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCL5—atherosclerosis	0.000101	0.00118	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LDLRAP1—atherosclerosis	9.98e-05	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR2—atherosclerosis	9.72e-05	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—atherosclerosis	9.71e-05	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MMP3—atherosclerosis	9.69e-05	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA2—atherosclerosis	9.66e-05	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PRKCG—atherosclerosis	9.58e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLTP—atherosclerosis	9.38e-05	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KNG1—atherosclerosis	9.25e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EDN1—atherosclerosis	9.22e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—UTS2—atherosclerosis	9.21e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGTR1—atherosclerosis	9.19e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL5—atherosclerosis	9.15e-05	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CX3CR1—atherosclerosis	8.83e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASR—atherosclerosis	8.83e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PRKCG—atherosclerosis	8.7e-05	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CX3CL1—atherosclerosis	8.66e-05	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VWF—atherosclerosis	8.66e-05	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOC3—atherosclerosis	8.61e-05	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDN1—atherosclerosis	8.58e-05	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LDLR—atherosclerosis	8.56e-05	0.001	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCL5—atherosclerosis	8.52e-05	0.000998	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AGT—atherosclerosis	8.43e-05	0.000987	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL3—atherosclerosis	8.36e-05	0.000979	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR2—atherosclerosis	8.21e-05	0.000962	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—atherosclerosis	8.21e-05	0.000961	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MMP3—atherosclerosis	8.19e-05	0.00096	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG8—atherosclerosis	8.13e-05	0.000953	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LTA4H—atherosclerosis	8.13e-05	0.000953	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PRKCG—atherosclerosis	8.1e-05	0.000948	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NCF1—atherosclerosis	8e-05	0.000937	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDN1—atherosclerosis	7.79e-05	0.000913	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—F2—atherosclerosis	7.79e-05	0.000912	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL5—atherosclerosis	7.73e-05	0.000906	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AGT—atherosclerosis	7.65e-05	0.000897	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR2—atherosclerosis	7.56e-05	0.000885	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDNRA—atherosclerosis	7.56e-05	0.000885	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CYBA—atherosclerosis	7.52e-05	0.000881	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CG—atherosclerosis	7.45e-05	0.000873	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLAT—atherosclerosis	7.36e-05	0.000863	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GHRL—atherosclerosis	7.36e-05	0.000863	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PARP1—atherosclerosis	7.36e-05	0.000863	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCG—atherosclerosis	7.35e-05	0.000861	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VWF—atherosclerosis	7.32e-05	0.000857	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOC3—atherosclerosis	7.27e-05	0.000852	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LDLR—atherosclerosis	7.23e-05	0.000847	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AGT—atherosclerosis	7.12e-05	0.000834	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—F2—atherosclerosis	7.07e-05	0.000828	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL3—atherosclerosis	7.06e-05	0.000827	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—atherosclerosis	6.77e-05	0.000793	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NCF1—atherosclerosis	6.76e-05	0.000792	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—F2—atherosclerosis	6.58e-05	0.000771	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGT—atherosclerosis	6.47e-05	0.000758	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KNG1—atherosclerosis	6.46e-05	0.000757	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG1—atherosclerosis	6.43e-05	0.000753	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGTR1—atherosclerosis	6.43e-05	0.000753	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRA—atherosclerosis	6.39e-05	0.000748	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR2—atherosclerosis	6.39e-05	0.000748	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CYBA—atherosclerosis	6.36e-05	0.000745	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—atherosclerosis	6.3e-05	0.000738	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—atherosclerosis	6.3e-05	0.000738	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLG—atherosclerosis	6.26e-05	0.000733	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—atherosclerosis	6.22e-05	0.000729	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PARP1—atherosclerosis	6.22e-05	0.000729	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLAT—atherosclerosis	6.22e-05	0.000729	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FABP4—atherosclerosis	6.04e-05	0.000708	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LCAT—atherosclerosis	6.04e-05	0.000708	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—F2—atherosclerosis	5.98e-05	0.0007	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA4—atherosclerosis	5.93e-05	0.000695	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS3—atherosclerosis	5.93e-05	0.000695	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP7A1—atherosclerosis	5.83e-05	0.000683	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP3—atherosclerosis	5.73e-05	0.000671	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—atherosclerosis	5.72e-05	0.00067	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF2—atherosclerosis	5.7e-05	0.000668	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOB—atherosclerosis	5.54e-05	0.000648	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—atherosclerosis	5.49e-05	0.000643	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KNG1—atherosclerosis	5.46e-05	0.00064	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDN1—atherosclerosis	5.45e-05	0.000638	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGTR1—atherosclerosis	5.43e-05	0.000636	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL5—atherosclerosis	5.41e-05	0.000633	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP27A1—atherosclerosis	5.39e-05	0.000631	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—atherosclerosis	5.33e-05	0.000624	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLG—atherosclerosis	5.29e-05	0.00062	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LPL—atherosclerosis	5.29e-05	0.000619	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCG—atherosclerosis	5.14e-05	0.000602	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	5.11e-05	0.000598	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA2—atherosclerosis	5.11e-05	0.000598	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALOX15—atherosclerosis	5.11e-05	0.000598	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	5.11e-05	0.000598	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG5—atherosclerosis	5.04e-05	0.000591	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS3—atherosclerosis	5.01e-05	0.000587	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPP1—atherosclerosis	5.01e-05	0.000586	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—atherosclerosis	4.98e-05	0.000584	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPA—atherosclerosis	4.87e-05	0.000571	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP3—atherosclerosis	4.84e-05	0.000567	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF2—atherosclerosis	4.82e-05	0.000564	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BGN—atherosclerosis	4.72e-05	0.000553	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOB—atherosclerosis	4.68e-05	0.000548	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA5—atherosclerosis	4.67e-05	0.000547	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—atherosclerosis	4.64e-05	0.000543	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFB—atherosclerosis	4.63e-05	0.000543	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDN1—atherosclerosis	4.6e-05	0.000539	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL5—atherosclerosis	4.57e-05	0.000535	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGT—atherosclerosis	4.52e-05	0.00053	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	4.5e-05	0.000527	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LPL—atherosclerosis	4.47e-05	0.000523	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—atherosclerosis	4.43e-05	0.000519	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—atherosclerosis	4.43e-05	0.000519	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CAV1—atherosclerosis	4.39e-05	0.000514	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA1—atherosclerosis	4.38e-05	0.000513	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCG—atherosclerosis	4.34e-05	0.000509	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALOX5—atherosclerosis	4.34e-05	0.000509	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPP1—atherosclerosis	4.23e-05	0.000496	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—atherosclerosis	4.23e-05	0.000495	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—atherosclerosis	4.21e-05	0.000493	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—F2—atherosclerosis	4.18e-05	0.000489	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—atherosclerosis	4e-05	0.000468	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFB—atherosclerosis	3.91e-05	0.000459	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAMPT—atherosclerosis	3.89e-05	0.000456	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LIPC—atherosclerosis	3.87e-05	0.000453	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOC3—atherosclerosis	3.85e-05	0.000451	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK3—atherosclerosis	3.83e-05	0.000449	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LDLR—atherosclerosis	3.82e-05	0.000448	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGT—atherosclerosis	3.82e-05	0.000448	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—atherosclerosis	3.78e-05	0.000443	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—atherosclerosis	3.74e-05	0.000439	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—atherosclerosis	3.74e-05	0.000439	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CETP—atherosclerosis	3.73e-05	0.000437	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—atherosclerosis	3.72e-05	0.000436	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CAV1—atherosclerosis	3.71e-05	0.000435	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA1—atherosclerosis	3.7e-05	0.000434	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—atherosclerosis	3.66e-05	0.000429	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SCARB1—atherosclerosis	3.58e-05	0.000419	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—atherosclerosis	3.57e-05	0.000419	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2—atherosclerosis	3.53e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—atherosclerosis	3.48e-05	0.000407	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—atherosclerosis	3.38e-05	0.000396	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMGCR—atherosclerosis	3.38e-05	0.000396	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—atherosclerosis	3.32e-05	0.000389	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	3.24e-05	0.000379	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—atherosclerosis	3.2e-05	0.000375	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—atherosclerosis	3.15e-05	0.000369	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—atherosclerosis	3.09e-05	0.000362	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCA1—atherosclerosis	3.01e-05	0.000353	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—atherosclerosis	2.94e-05	0.000345	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	2.94e-05	0.000344	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—atherosclerosis	2.84e-05	0.000333	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—atherosclerosis	2.81e-05	0.000329	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—atherosclerosis	2.8e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—atherosclerosis	2.66e-05	0.000312	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKB1—atherosclerosis	2.63e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK8—atherosclerosis	2.59e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—atherosclerosis	2.58e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—atherosclerosis	2.58e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	2.49e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOB—atherosclerosis	2.47e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.41e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	2.4e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	2.39e-05	0.00028	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—atherosclerosis	2.37e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—atherosclerosis	2.37e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPL—atherosclerosis	2.36e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—atherosclerosis	2.3e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	2.26e-05	0.000265	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—atherosclerosis	2.25e-05	0.000264	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD36—atherosclerosis	2.24e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	2.23e-05	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	2.19e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	2.19e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	2.18e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.13e-05	0.000249	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARA—atherosclerosis	2.09e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	2.02e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGT—atherosclerosis	2.02e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—atherosclerosis	2e-05	0.000234	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—atherosclerosis	1.98e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAV1—atherosclerosis	1.96e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA1—atherosclerosis	1.96e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	1.91e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	1.85e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.79e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—atherosclerosis	1.72e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—atherosclerosis	1.69e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—atherosclerosis	1.65e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—atherosclerosis	1.55e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—atherosclerosis	1.53e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—atherosclerosis	1.48e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—atherosclerosis	1.4e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.36e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—atherosclerosis	1.29e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—atherosclerosis	6.82e-06	7.99e-05	CbGpPWpGaD
